Search research articles
Contact Us
Filters
Showing results (31-40 of 53) with videos related to
Page
of 6
Sort By:
The New England Journal of Medicine
|
March 2, 2012
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Leukemia Research
|
January 11, 2007
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)
Ruben A Mesa, Srdan Verstovsek, Francisco Cervantes, et al.
Blood Advances
|
October 26, 2020
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase
John O Mascarenhas, Raajit K Rampal, Heidi E Kosiorek, et al.
Research Square
|
February 12, 2026
Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells
James Riley, Mosha Deng, Tanishk Sinha, et al.
Transplantation and Cellular Therapy
|
March 28, 2024
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
Muna Qayed, Urvi Kapoor, Scott Gillespie, et al.
Blood
|
September 12, 2022
Effective treatment of low-risk acute GVHD with itacitinib monotherapy
Aaron Etra, Alexandra Capellini, Amin Alousi, et al.
Transplantation and Cellular Therapy
|
December 12, 2024
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group
Nikolaos Katsivelos, Nikolaos Spyrou, Daniela Weber, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 4, 2020
Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Aaron T Gerds, Jason Gotlib, Prithviraj Bose, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 8, 2022
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Aaron T Gerds, Jason Gotlib, Haris Ali, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
January 22, 2026
Phase I study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers
Julie S Barber-Rotenberg, Andrew R Haas, Charu Aggarwal, et al.
Page
of 6
Search research articles
Search
Showing results (31-40 of 53) with videos related to
Sort By:
Page
of 6
The New England Journal of Medicine
|
March 2, 2012
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Leukemia Research
|
January 11, 2007
Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT)
Ruben A Mesa, Srdan Verstovsek, Francisco Cervantes, et al.
Blood Advances
|
October 26, 2020
Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase
John O Mascarenhas, Raajit K Rampal, Heidi E Kosiorek, et al.
Research Square
|
February 12, 2026
Cell-derived Nanoparticles Provide a Robust Platform to Manufacture Therapeutic T cells
James Riley, Mosha Deng, Tanishk Sinha, et al.
Transplantation and Cellular Therapy
|
March 28, 2024
A Validated Risk Stratification That Incorporates MAGIC Biomarkers Predicts Long-Term Outcomes in Pediatric Patients with Acute GVHD
Muna Qayed, Urvi Kapoor, Scott Gillespie, et al.
Blood
|
September 12, 2022
Effective treatment of low-risk acute GVHD with itacitinib monotherapy
Aaron Etra, Alexandra Capellini, Amin Alousi, et al.
Transplantation and Cellular Therapy
|
December 12, 2024
Serial Clinical and Biomarker Monitoring during Graft-Versus-Host Disease Treatment Identifies Distinct Risk Strata Including an Ultra-Low Risk Group
Nikolaos Katsivelos, Nikolaos Spyrou, Daniela Weber, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 4, 2020
Myeloid/Lymphoid Neoplasms with Eosinophilia and TK Fusion Genes, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology
Aaron T Gerds, Jason Gotlib, Prithviraj Bose, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
September 8, 2022
Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology
Aaron T Gerds, Jason Gotlib, Haris Ali, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy
|
January 22, 2026
Phase I study of autologous T cells bearing fully human chimeric antigen receptors targeting mesothelin in mesothelin-expressing cancers
Julie S Barber-Rotenberg, Andrew R Haas, Charu Aggarwal, et al.
Page
of 6